China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

Market Cap	13.73B
Revenue (ttm)	1.85B
Net Income (ttm)	306.36M
Shares Out	504.25M
EPS (ttm)	0.61
PE Ratio	44.63
Forward PE	23.86
Dividend	0.32 (1.18%)
Ex-Dividend Date	May 28, 2025

Volume	8,297,276
Average Volume	6,848,750
Open	26.88
Previous Close	27.41
Day's Range	26.88 - 27.45
52-Week Range	25.33 - 41.98
Beta	0.13
RSI	54.62
Earnings Date	Aug 23, 2025

About SHE:300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,938
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2024, SHE:300294's revenue was 1.73 billion, a decrease of -34.58% compared to the previous year's 2.65 billion. Earnings were 396.99 million, an increase of 67.18%.